SUMMARY
cells. We found that diacylglycerol kinase (DGK) inhibitor II (R59949) decreased caspase-3/7 activity after serum withdrawal in striatal
Hdh
111Q/111Q cells. In addition, R59949 decreased the accumulation of a 513 amino acid N-terminal Htt fragment processed by caspase-3, and blocked alterations in lipid metabolism during serum withdrawal. To identify the diacylglycerol kinase mediating this effect, we knocked down all four DGK isoforms expressed in the brain (beta, gamma, epsilon and zeta) using siRNA. Only the knockdown of the family member, DGK-epsilon (DGKε), blocked striatal Hdh 111Q/111Q -mediated toxicity. We also investigated the significance of these findings in vivo. First, we found that reduced function of the Drosophila DGKε homolog significantly improves Httinduced motor dysfunction in a fly model of HD. In addition, we find that the levels of DGKε are increased in the striatum of R6/2 HD transgenic mice when compared to littermate controls. Together these findings indicate that increased levels of kinase DGKε contribute to HD pathogenesis, and suggest that reducing its levels or activity is a potential therapy for HD. ____________________________________ Huntington's disease (HD) is caused by a polyglutamine (polyQ) expansion in the Nterminus of the protein huntingtin (Htt) (1) . A pathological change in HD brain is the massive loss of medium spiny neurons in the striatum and loss of neurons in the cortex as the disease progresses. HD results in chorea, dementia and eventually death. As there is no cure for HD, new therapeutic treatments are clearly needed. Protein kinases are the second most important group of drug targets, after G-protein-coupled receptors.
The kinase superfamily, whose members are related in the sequence and structure of their catalytic domain, includes CGMC kinases, CaMK kinases, serine-threonine kinases, tyrosine kinases, AGC kinases, and others. Because of their key roles in modulating signal transduction and gene transcription, protein kinases are considered to be important potential targets for drug therapy. We therefore evaluated kinase inhibitors in an HD cellular model and identified diacylglycerol kinases (DGKs) in our cellular screen.
DGKs consist of a family of kinases that catalyze the phosphorylation of diacylglycerol (DAG) to produce phosphatidic acid (PA) (2) . Both DAG and PA are important intracellular signaling molecules (2) . DAG can activate protein kinase C (PKC), Ras guanyl-nucleotidereleasing protein (RasGRP), and transient receptor potential (TRP) channels (3, 4) . TRP channels mediate store operated calcium entry into HD medium spiny neurons and recently compounds that target these channels have been shown to block HD neurotoxicity (5) . There are 10 human DGK isoforms and each has unique biochemical properties, expression patterns and subcellular localization. These enzymes have a DAG binding C1 and catalytic domain. DGK-epsilon (DGKε) is unique in that it has preference for substrate selection. DGKε favors DAG with 1-stearoyl-2-arachidonoyl (18:0, 20:4) acyl chains, which represent the prevalent acyl chain composition in phosphatidylinositol (PI) and its derivatives (6) . The DGKε knockout mouse showed reduced seizure in response to electroconvulsive shock (7) . Also, DGKε knockout mouse had lower content of PI with 1-stearoyl-2-arachidonoyl acyl chains (8 
EXPERIMENTAL PROCEDURES
Cell Culture-All cell culture reagents were from Invitrogen unless otherwise stated. Striatal Hdh Q7/Q7 and Hdh Q111/Q111 cells were maintained in Dulbecco's modified eagle medium (DMEM) supplemented with 10% FBS at 33°°C. Culture plates were coated with 50ug/ml rat tail collagen type-I (BD) for 1 h at room temperature before immortalized striatal cells were seeded for experiments. For caspase-3/7 activity assay, Biocoat collagen I coated 96-well plates from BD were used. Knocking down DGK genes was achieved by transfecting corresponding Dharmacon siGENOME SMARTpool siRNAs (Thermo Scientific) via Amaxa Nucleofector kit L (Lonza).
Caspase-3/7
Activity Assay-The caspase activity assay was performed with Apo3 HTS kit (Cell Technology -ΔΔCp method was used to determine the relative expression level of each gene normalized against the housekeeping gene β-actin (ActB). The specificity of each pair of primers was tested by comparing to a negative control sample of water. The primers used are:
The primer concentration was 400nM for the qPCR.
Lipid Extraction-Cells in a 15 cm plate were placed on ice and then washed once with ice cold PBS, scraped in PBS on ice and centrifuged. The pellet was suspended in 1200 μl ice cold 1:1 chloroform (CHCl 3 )/methanol (MeOH) (14) . After vortex for 1 min to mix, cells were centrifuged and the supernatant was discarded. To the pellet, 600 μl 2:1 ice-cold CHCl 3 /MeOH with 0.25% 12N hydrochloric acid (HCl) was added followed by 10 min vortex at 4°C. Then 120 μl 1N HCl was added and the mixture was vortexed for 15 s followed by centrifuge at 3500 rpm for 5 min. The lower phase was collected and dried under the protection of nitrogen. The pellet was redissolved in 200 μL of 1:1 CHCl 3 /MeOH with 30 mM piperidine before multiple reaction monitoring (MRM)-MS analysis.
Mass Spectrometry Profiling-To profile the lipids in the extracts, samples were first analysed by MALDI-MS using a vMALDI-LTQ platform (Thermo) operating in the negative ion mode. Briefly, 1 μl of matrix (2,5-dihydroxybenzoic acid, DHB, dissolved in methanol at 10 mg/100 μl) was gently mixed with 1 μl of extracted phospholipid in 1:1 CHCl 3 /MeOH solution with piperidine, and the mixture was loaded on an MALDI plate specially marked with ImmEdge Hydrophobic Barrier Pen (Vector Laboratories, Inc.). The laser power was adjusted to optimize the MALDI signal and spectra were acquired over m/z 300-2000.
Mass Spectrometry MRM-MS Analysis
Samples were analyzed by MRM-MS on a 4000 QTRAP hybrid triple quadrupole/linear ion trap mass spectrometer (AB Sciex) equipped with a Turbo IonSpray source in negative ion mode. Lipid samples were introduced by direct infusion using a syringe pump (Mode 11 series, Harvard Apparatus) at a flow rate of 10 μl/min. A total of 18 ion transition pairs from 6 base phosphoinositides (34:1, 36:1, 36:4, 38:4, 38:5, 40:6) with one, two, or three phosphate moieties (PI, PIP and PIP 2 ) were quantified by MRM-MS. The negatively charged parent ion was used as the Q1 mass and the diagnostic fragment ion of the dehydrated head-group was chosen for Q3 (15) , which differentiates phosphoinositides with different fatty acid compositions ( Supplementary Fig. 1 ). The Q1 m/z, Q3 m/z, dwell time, declustering potential, collision energy, and collision cell exit potential for each transition are listed in Supplementary Table 1 . PIP 3 species were not included in the study due to their extremely low abundance. Data was collected with an ion spray voltage of -4500 V, curtain gas of 10 psi, nebulizer gas of 25 psi, and an interface heater temperature of 600°C. MRM-MS transitions were acquired and monitored at unit resolution in both Q1 and Q3. Each sample was typically infused for 3-6 min and each sample was analyzed two times with the average signal of the runs reported. Quantification was performed using Analyst 1.5 and each transition was individually integrated. The quantification results were normalized against cell numbers counted by Z1 Coulter Particle Counter (Beckman Coulter).
Drosophila
Motor Performance Analysis Tests were carried out using 15 age-matched virgin females. Animals were placed in an empty vial and tapped down.
The number of animals able to climb 9 cm after 15 sec was recorded as a percentage of the total. This was repeated 10 consecutive times and the average of the ten observations was plotted for each day shown in the chart. Two replicates were tested in parallel for each genotype. Animals were raised at 26.5°C. The nervous system driver line elav-GAL c155 was obtained from the Bloomington Drosophila Stock Center at University of Indiana (http://flystocks.bio.indiana.edu). The inducible shRNA line targeting the Drosophila homolog of DGKε (4659GD) was obtained from the Vienna Drosophila RNAi Center (http://stockcenter.vdrc.at/ control/main). NT-Htt128Q animals express an N-terminal Htt fragment comprising exons 1-4 (first 336 amino acids with 128Q polyglutamine expansion) have been previously described (16) . (Fig. 1A) . However, when coupled with WST-8 assay, which measures bioreduction of WST-8 mostly dependent on the glycolytic NAD(P)H production of viable cells, DGK inhibitor II (R59949) and rapamycin were the only kinase inhibitors which protected Hdh 111Q/111Q cells against serum withdrawal (Fig. 1B) thus indicating that these compounds act specifically on Hdh 111Q/111Q -induced toxicity. Rapamycin has been reported to reduce HD associated toxicity through induction of autophagy (18) . The identification of DGK inhibitor II as blocking mutant-Htt toxicity is novel and the mechanism of action for this effect is not known. To confirm that other DGK inhibitors were effective in this assay, we tested another DGK inhibitor, DGK inhibitor I (DGKi-I, also known as R59022). As shown in Fig. 2A Fig. 2 ). Given this result we utilized Hdh 111Q/111Q cells for most of our studies.
RESULTS

Kinase Inhibitor Library Screening
Mutant Huntingtin Proteolysis is Reduced in Cells Treated with DGK Inhibitor II-
The proteolysis of mutant Htt by caspases to generate the toxic N-terminal fragments is directly linked to the cell death mechanisms in HD. In Hdh 111Q/111Q cells, proteolysis of Htt was detected upon serum withdrawal (Fig. 2B, lane 2) using western blot analysis. Addition of either DGK inhibitor I or II reduced the level of Htt proteolysis (Fig. 2B,  lane 3,4,6 ). Using an antibody specific to the caspase-3 cleavage site at 513 amino acid of Htt (NeoHtt513), we found that Htt proteolysis at this site was induced by serum starvation (Fig 2B, lane 2) and reduced by treatment with DGK inhibitors (Fig. 2B, lane  3,4,6 ). We did not detect cleavage of Htt at amino acids 552 or 586 using neoHtt552 or neoHtt586 under these conditions (data not shown). Immunocytochemistry revealed that cleaved active caspase-3 was induced in cells was not altered by co-treatment of bisindolylmaleimide I or Gö6983 using caspase activity (Fig. 3A) , WST-8 (Fig. 3B) or the proteolysis of Htt (Fig. 3C) and Hdh 111Q/111Q . Representative MALDI-MS spectra are shown in Supplementary Fig.  4-8 cells. Furthermore, the levels of PIP increased during serum withdrawal and were reduced by DGK inhibitor II treatment (Fig. 4C) .
Identification
of DGKε as a Therapeutic Target for HD-There are 10 DGK mammalian isoforms and therefore it is possible that one or several of these family members are possible therapeutic targets of the DGK inhibitors in the context of HD toxicity. Five DGK isoforms, α, β, γ, ε and ξ have been shown to be expressed in the brain (19) . To identify the isoforms most abundant in the striatum, we used reverse transcription quantitative PCR (RT-qPCR) to quantify the isoforms in this region of the brain. β, γ, ε and ξ DGK isoforms were expressed in the striatum (Fig. 5) . We then knocked down these 4 DGKs in striatal Hdh 111Q/111Q cells individually with siRNA and performed the caspase activity assay after serum starvation. Only the siRNA specific to DGKε resulted in decreased caspase-3/7 activity, similar to treatment of DGK inhibitors (Fig. 6A , data not shown for other DGKs). We confirmed the knockdown of DGKε using RT-qPCR (Fig. 6B) and the level was similar in magnitude to that found for the reduction in caspase-3/7 activity (Fig.  6A) .
We also investigated whether the levels of DGKε are altered in response to mutant Htt. RT-qPCR for DGKε showed that Hdh 111Q/111Q cells have higher levels of DGKε than Hdh 7Q/7Q cells (Fig. 6C) indicating that DGKε levels are increased in response to mutant Htt.
In Vivo Evidence for DGKε-Reduction in the Levels of DGK Epsilon Homolog Improves Neuronal Function in a Drosophila Model of HD-We next sought to validate this observation in vivo.
We found that in the striatum of R6/2 HD transgenic mice, a HD mice model with over-expression of N-terminal fragment of Htt containing approximately 120 polyQ, the levels of DGKε are higher than in the striatum of littermate control mice (Fig. 7A) . These results suggest a specific role of DGKε in HD toxicity.
The above data suggest that DGKε is involved in HD and may function as a suppressor of Htt-induced toxicity in vivo. To investigate this possibility, we studied the effect of decreasing DGKε levels in a well-established Drosophila HD model (16) . Expression of N-terminal Htt with a 128Q (NT-Htt128Q) expansion in the Drosophila nervous system (using the neuronal elav-GAL4 driver) leads to progressive motor performance deficits when compared with normal animals (Fig. 7B, 
DISCUSSION
To identify new therapeutic targets in HD, we screened a kinase inhibitor library for molecules that block mutant Htt cellular toxicity. We found that DGK inhibitor II decreased caspase-3/7 activity after serum withdrawal in striatal Hdh 111Q/111Q cells. Our screen also identified rapamycin as a kinase inhibitor that blocked mutant Htt-mediated cell death. The DGK inhibitor II decreased the level of cleaved caspase-3, the accumulation of the 513 amino acid Nterminal Htt fragment processed by caspase-3, and blocked alterations in lipid metabolism during serum withdrawal. We also tested the DGK inhibitor I that was not in the initial library of 80 compounds and this compound was effective as well.
There are ten distinct mammalian isoforms of DGKs.
To identify the possible diacylglycerol kinase family member that was responsible for rescuing striatal Hdh 111Q/111Q -mediated toxicity, we knocked down all four DGK isoforms expressed in the brain (beta, gamma, epsilon and zeta) using siRNA. Only the knockdown of the family member, DGK-epsilon, blocked striatal Hdh 111Q/111Q -mediated toxicity. This isoform DGKε is unique in it has a hydrophobic domain that facilitates attachment to membranes (20) and further it has specificity for diacylglycerol containing arachidonyl chains (21, 22) . Loss of function of the Drosophila DGKε homolog was evaluated in a HD Drosophila model, and we found significant improvement of Httinduced motor dysfunction. In addition, the levels of DGK-epsilon were higher in the striatum of R6/2 HD transgenic mice when compared to controls, confirming the relevance of the interaction in vivo.
We have discovered that inhibition of the enzyme DGK is protective to immortalized striatal cells expressing mutant Htt. Since the enzymatic activity of this protein is to catalyze the phosphorylation of DAG into PA, we expect that inhibition would lead to a rise in DAG production and decreased PA production. Classically DGKs are known as regulators of PKC family members. However, we tested PKCs inhibitors and we did not find the protection imparted by DGK inhibition was dependent upon PKCs for mutant Htt toxicity. cells undergoing serum withdrawal we found the levels of PIP and PIP 2 were significantly reduced. Correlating with this immunocytochemistry demonstrated an increase in PIP signaling during serum withdrawal which was blocked by DGK inhibition. This may be relevant to the protective effect of DGK inhibition.
A number of alterations in lipid metabolism have been noted before in HD. This includes lower cholesterol levels in affected areas of the brain (23) and reduced ganglioside (GM1) synthesis (24) . Further modulation of GM1 restores normal motor behaviour in HD mouse model YAC128 (25) . Our findings further emphasize the role of altered lipid metabolism in HD particularly with respect to phosphatidylinositols. Phosphatidyl-inositol and phosphatidylinositol phosphates (PIPs) which are already known to have distinct binding to the mutant Htt protein. This may be particularly important as the normal function of Htt appears to be involved in vesicular trafficking and many protein complexes involved in this process require PIPs. Htt binds different forms of PIPs while the mutant Htt bound to a subset of PIPs more strongly than wild type Htt in vesiclebinding assays (9) . Therefore, inhibition of DGKs may alter the interaction of mutant Htt with PIPs. DGKε levels as measured by RT-qPCR appear to be modulated by polyglutamine expansion in the Htt protein. We found higher levels of DGKε in immortalized striatal cells expressing mutant Htt and in the mouse model of R6/2 HD transgenic mouse model. Further, cells undergoing cell death had increased levels of DGKε. This may increase the levels of PIP 2 which is known to regulate cell death through P2X7 receptors (26) .
In conclusion, we have identified DGKε as a therapeutic target for HD. We have shown that pharmacological inhibition of DGK activity can improve Htt-induced toxicity in cells. In addition we show that the abnormal phospholipid levels induced by mutant Htt are restored upon decreasing DGK activity. Finally, we have also observed in vivo, that DGKε levels are increased in response to Htt and that decreasing DGKε levels rescues Htt-toxicity in an animal model. There are DGKε mutant mice available (7, 8) and our future work will be aimed at how modulation of this enzyme in mammalians affects disease progression and neuropathology in HD mouse models. 111Q/111Q cells were generously provided by Dr. Marcy MacDonald (Massachusetts General Hospital). We would also acknowledge the support of mass spectrometry instrumentation through the NCRR shared instrumentation program grant S10 RR027953 (BG) and the Mass Spectrometry and Imaging Core funded through PL1 AG032118 (BG). Table 2 for further details of kinase inhibitors used in this screen. 
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